S
SynAct Pharma AB
STO:SYNACT
SynAct Pharma AB
STO:SYNACT
Price:
19.7
SEK
-4.37%
Market Cap:
kr1.1B
Balance Sheet
Balance Sheet Decomposition
SynAct Pharma AB
SynAct Pharma AB
Balance Sheet Decomposition is not available for
SynAct Pharma AB
SynAct Pharma AB
Balance Sheet
SynAct Pharma AB
SynAct Pharma AB
Currency: SEK
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
27
|
10
|
7
|
4
|
15
|
24
|
108
|
62
|
61
|
|
| Cash Equivalents |
27
|
10
|
7
|
4
|
15
|
24
|
108
|
62
|
61
|
|
| Total Receivables |
3
|
4
|
6
|
5
|
6
|
11
|
15
|
12
|
14
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
17
|
0
|
18
|
|
| Total Current Assets |
29
|
14
|
13
|
8
|
21
|
35
|
140
|
75
|
94
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
3
|
2
|
1
|
2
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
3
|
2
|
1
|
2
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
|
| Intangible Assets |
1
|
1
|
1
|
1
|
0
|
0
|
0
|
152
|
155
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
14
|
0
|
0
|
0
|
0
|
20
|
|
| Total Assets |
31
N/A
|
15
-50%
|
14
-8%
|
24
+70%
|
22
-9%
|
38
+78%
|
143
+272%
|
228
+60%
|
271
+19%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
3
|
2
|
3
|
5
|
3
|
4
|
5
|
10
|
17
|
|
| Accrued Liabilities |
0
|
1
|
0
|
5
|
3
|
10
|
5
|
14
|
10
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
1
|
4
|
1
|
0
|
|
| Total Current Liabilities |
3
|
2
|
4
|
10
|
6
|
15
|
15
|
25
|
28
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
2
|
1
|
0
|
1
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
18
|
18
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
9
|
8
|
|
| Total Liabilities |
3
N/A
|
2
-34%
|
4
+61%
|
10
+177%
|
6
-44%
|
18
+206%
|
16
-8%
|
52
+222%
|
56
+9%
|
|
| Equity | ||||||||||
| Common Stock |
2
|
2
|
2
|
2
|
3
|
3
|
4
|
4
|
6
|
|
| Retained Earnings |
16
|
31
|
46
|
78
|
107
|
176
|
272
|
475
|
555
|
|
| Additional Paid In Capital |
41
|
42
|
55
|
90
|
119
|
194
|
395
|
647
|
763
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
27
N/A
|
13
-52%
|
10
-20%
|
14
+31%
|
16
+18%
|
21
+32%
|
127
+506%
|
176
+39%
|
214
+22%
|
|
| Total Liabilities & Equity |
31
N/A
|
15
-50%
|
14
-8%
|
24
+70%
|
22
-9%
|
38
+78%
|
143
+272%
|
228
+60%
|
271
+19%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
13
|
13
|
15
|
17
|
25
|
26
|
30
|
36
|
46
|
|
Switch to:
Switch to:
See Also
Discover More
